Research map: Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMT

Back to the article

Papers in this map

  1. A Proportional Hazards Model for the Subdistribution of a Competing Risk · Jason P. Fine · 1999 · 13928 citations · Cited by this paper
  2. Expanding the conditioning armamentarium in adult acute lymphoblastic leukaemia: is treosulfan ready to challenge total body irradiation? · M. Joseph John · 2026 · Cites this paper
  3. Allogeneic stem cell transplantation in adult Ph-like acute lymphoblastic leukemia. Results from two consecutive GIMEMA protocols · 2026 · Related
  4. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators · Ted Alan Gooley · 1999 · 2694 citations · Cited by this paper
  5. Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities · 2026 · Related
  6. Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study · Christina Peters · 2020 · 348 citations · Cited by this paper
  7. Institutional risk management for out-of-specification commercial CAR-T products · 2026 · Related
  8. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation · Jochen Casper · 2003 · 151 citations · Cited by this paper
  9. The 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation: Data Management Group – Poster Session (P973–P983) · 2026 · Related
  10. DNA alkylation and interstrand cross-linking by treosulfan · John Anthony Hartley · 1998 · 122 citations · Cited by this paper
  11. Vaccination in haematopoietic stem cell transplantation and cellular therapies: consensus, divergence, and uncertainties in global practice · 2026 · Related
  12. Extreme heterogeneity of myeloablative total body irradiation techniques in clinical practice: A survey of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation · Sebastian Giebel · 2014 · 108 citations · Cited by this paper
  13. CAR-T TEMRA and CAR-Tregs in vivo expansion are both associated with a poor response after CD19.CAR-T therapy · 2026 · Related
  14. Summary of Scientific and Statistical Methods, Study Endpoints and Definitions for Observational and Registry-Based Studies in Hematopoietic Cell Transplantation · Abraham Sebastian Kanate · 2019 · 102 citations · Cited by this paper
  15. The 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards · 2026 · Related
  16. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications · Dietrich Wilhelm Beelen · 2004 · 99 citations · Cited by this paper
  17. Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysis · 2026 · Related
  18. Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Hematologic Malignancies After Dose-Escalated Treosulfan/Fludarabine Conditioning · Jochen Casper · 2010 · 95 citations · Cited by this paper
  19. EASIX and sC5b-9 for early identification of adults at high risk of developing TA-TMA after allo-HCT · 2026 · Related
  20. Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial · Dietrich Wilhelm Beelen · 2022 · 68 citations · Cited by this paper
  21. Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors · Ralf Axel Hilger · 1998 · 64 citations · Cited by this paper
  22. Treosulfan as an Effective Second-Line Therapy in Ovarian Cancer · M. Gropp · 1998 · 60 citations · Cited by this paper
  23. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome · Nicolaus Martin Kröger · 2001 · 57 citations · Cited by this paper
  24. Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia · on behalf of the EBMT paediatric diseases working party · 2014 · 49 citations · Cited by this paper
  25. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma · Martin Schmidt‐Hieber · 2007 · 42 citations · Cited by this paper
  26. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations · Raffaella Greco · 2025 · 42 citations · Cited by this paper
  27. Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL) · Iduna Fichtner · 2003 · 41 citations · Cited by this paper
  28. Busulfan–fludarabine- or treosulfan–fludarabine-based myeloablative conditioning for children with thalassemia major · Roswitha Lüftinger · 2022 · 35 citations · Cited by this paper
  29. Treosulfan and fludarabine low‐toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia · Jerzy Hołowiecki · 2008 · 30 citations · Cited by this paper
  30. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results · Partow Kebriaei · 2016 · 29 citations · Cited by this paper
  31. Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high‐risk patients · DONATELLA BARONCIANI · 2008 · 25 citations · Cited by this paper
  32. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced‐intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT · Avichai Shimoni · 2021 · 24 citations · Cited by this paper
  33. Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial · Karl‐Walter Sykora · 2023 · 24 citations · Cited by this paper
  34. Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies · Ronit Yerushalmi · 2015 · 23 citations · Cited by this paper
  35. Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the Acute Leukemia Working Party of the EBMT · Alexandros Spyridonidis · 2023 · 21 citations · Cited by this paper
  36. Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT · Francesco Saraceni · 2023 · 21 citations · Cited by this paper
  37. Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP) · Eleni Gavriilaki · 2022 · 16 citations · Cited by this paper
  38. Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL) · Nicolaus Martin Kröger · 2015 · 15 citations · Cited by this paper
  39. Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party · Jesús Duque‐Afonso · 2022 · 15 citations · Cited by this paper

Source: OpenAlex (CC0)